Furthermore, blockade of AKT signaling pathway by MK2206 recovered the sensitivity of PC9-Mer cells to erlotinib treatment (Fig. 5E), suggesting that Mer expression could be an advantage for cancer cells by enhancing drug resistance through sustained AKT activation. Here, AKT1 is linked to cancer.